Johnson & Johnson has proposed a $5.5 billion settlement to resolve roughly 76,000 lawsuits alleging its talc products cause ovarian cancer. The agreement requires participation from at least 95% of eligible claimants, does not cover future lawsuits, and could ultimately cost more than the headline figure, with an attorney telling Reuters the payout could reach $7 billion or more. The company ended fiscal Q2 2026 with about $21 billion in cash and marketable securities and expects to pay up to $3 billion in 2027, followed by additional payments beginning in 2028. A federal judge has cast doubt on individual plaintiffs' ability to prove talc caused their cancer, suggesting J&J is settling from a position of improved legal strength. The settlement would reduce a major legal overhang but not eliminate talc liability entirely.
Johnson & JohnsonProposed $5.5B settlement reduces legal overhang, though not fully eliminating talc liability.
